Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Lung Cancer

  Free Subscription


Articles published in Int J Cancer

Retrieve available abstracts of 201 articles:
HTML format



Single Articles


    April 2021
  1. CAI L, Chen Y, Tong X, Wu X, et al
    The genomic landscape of young and old lung cancer patients highlights age-dependent mutation frequencies and clinical actionability in young patients.
    Int J Cancer. 2021 Apr 2. doi: 10.1002/ijc.33583.
    PubMed     Abstract available


    March 2021
  2. TEN HAAF K, van der Aalst CM, de Koning HJ, Kaaks R, et al
    Personalising lung cancer screening: an overview of risk-stratification opportunities and challenges.
    Int J Cancer. 2021 Mar 30. doi: 10.1002/ijc.33578.
    PubMed     Abstract available


  3. TAKADA K, Shimokawa M, Takamori S, Shimamatsu S, et al
    Clinical impact of probiotics on the efficacy of anti-PD-1 monotherapy in patients with non-small cell lung cancer: A multicenter retrospective survival analysis study with inverse probability of treatment weighting.
    Int J Cancer. 2021 Mar 15. doi: 10.1002/ijc.33557.
    PubMed     Abstract available


    February 2021
  4. LOW JL, Huang Y, Sooi K, Ang Y, et al
    Low dose pembrolizumab in the treatment of advanced non-small cell lung cancer.
    Int J Cancer. 2021 Feb 26. doi: 10.1002/ijc.33534.
    PubMed     Abstract available


  5. KRILAVICIUTE A, Brenner H
    Low positive predictive value of computed tomography screening for lung cancer irrespective of commonly employed definitions of target population.
    Int J Cancer. 2021 Feb 26. doi: 10.1002/ijc.33522.
    PubMed     Abstract available


  6. HATA A, Nakajima T, Matsusaka K, Fukuyo M, et al
    Genetic alterations in squamous cell lung cancer associated with idiopathic pulmonary fibrosis.
    Int J Cancer. 2021 Feb 3. doi: 10.1002/ijc.33499.
    PubMed     Abstract available


    December 2020
  7. DANIEL D, Kuchava V, Bondarenko I, Ivashchuk O, et al
    Trilaciclib prior to chemotherapy and atezolizumab in patients with newly diagnosed extensive-stage small cell lung cancer: a multicentre, randomised, double-blind, placebo-controlled phase II trial.
    Int J Cancer. 2020 Dec 21. doi: 10.1002/ijc.33453.
    PubMed     Abstract available


  8. ZHU J, Smith-Warner SA, Yu D, Zhang X, et al
    Associations of coffee and tea consumption with lung cancer risk.
    Int J Cancer. 2020 Dec 16. doi: 10.1002/ijc.33445.
    PubMed     Abstract available


    November 2020
  9. WU YL, Zhang L, Fan Y, Zhou J, et al
    Randomized Clinical Trial of Pembrolizumab Versus Chemotherapy for Previously Untreated Chinese Patients With PD-L1-Positive Locally Advanced or Metastatic Non-Small-Cell Lung Cancer: KEYNOTE-042 China Study.
    Int J Cancer. 2020 Nov 24. doi: 10.1002/ijc.33399.
    PubMed     Abstract available


  10. JIN K, Hung RJ, Thomas S, Le Marchand L, et al
    Hormonal factors in association with lung cancer among Asian women: a pooled analysis from the International Lung Cancer Consortium.
    Int J Cancer. 2020 Nov 19. doi: 10.1002/ijc.33405.
    PubMed     Abstract available


  11. GIRON P, Eggermont C, Noeparast A, Vandenplas H, et al
    Targeting USP13 mediated drug tolerance increases the efficacy of EGFR inhibition of mutant EGFR in Non-Small Cell Lung Cancer.
    Int J Cancer. 2020 Nov 19. doi: 10.1002/ijc.33404.
    PubMed     Abstract available


  12. XUE R, Sheng Y, Duan X, Yang Y, et al
    Tie2-expressing monocytes as a novel angiogenesis-related cellular biomarker for non-small cell lung cancer.
    Int J Cancer. 2020 Nov 5. doi: 10.1002/ijc.33381.
    PubMed     Abstract available


    October 2020
  13. WAH W, Stirling RG, Ahern S, Earnest A, et al
    Influence of Timeliness and Receipt of First Treatment on Geographic Variation in Non-small Cell Lung Cancer Mortality.
    Int J Cancer. 2020 Oct 12. doi: 10.1002/ijc.33343.
    PubMed     Abstract available


    September 2020
  14. GONZALEZ MALDONADO S, Motsch E, Trotter A, Kauczor HU, et al
    Overdiagnosis in lung cancer screening - estimates from the German Lung Cancer Screening Intervention Trial.
    Int J Cancer. 2020 Sep 15. doi: 10.1002/ijc.33295.
    PubMed     Abstract available


  15. ZHOU W, Liu G, Hung RJ, Haycock PC, et al
    Causal Relationships between Body Mass Index, Smoking, and Lung Cancer: Univariable and Multivariable Mendelian Randomization.
    Int J Cancer. 2020 Sep 11. doi: 10.1002/ijc.33292.
    PubMed     Abstract available


  16. DUDNIK E, Moskovitz M, Agbarya A, Gottfried T, et al
    Alternative nivolumab duration and scheduling in advanced non-small cell lung cancer (aNSCLC): a real-world evidence.
    Int J Cancer. 2020 Sep 1. doi: 10.1002/ijc.33281.
    PubMed     Abstract available


    August 2020
  17. GRAU N, Scherer SD, Rothley M, Rosswag S, et al
    Spatiotemporally controlled induction of gene expression in vivo allows tracking the fate of tumor cells that traffic through the lymphatics.
    Int J Cancer. 2020;147:1190-1198.
    PubMed     Abstract available


  18. YOO JE, Han K, Shin DW, Park SH, et al
    Conditional relative survival and competing mortality in patients who underwent surgery for lung cancer: a nationwide cohort study.
    Int J Cancer. 2020 Aug 1. doi: 10.1002/ijc.33239.
    PubMed     Abstract available


  19. WALPOLE E, Dunn N, Youl P, Harden H, et al
    Nonbreast cancer incidence, treatment received and outcomes: Are there differences in breast screening attendees versus nonattendees?
    Int J Cancer. 2020;147:856-865.
    PubMed     Abstract available


  20. VAN DER WILLIK KD, Ruiter R, van Rooij FJA, Verkroost-van Heemst J, et al
    Ascertainment of cancer in longitudinal research: The concordance between the Rotterdam Study and the Netherlands Cancer Registry.
    Int J Cancer. 2020;147:633-640.
    PubMed     Abstract available


  21. CARIOLI G, Bertuccio P, Malvezzi M, Rodriguez T, et al
    Cancer mortality predictions for 2019 in Latin America.
    Int J Cancer. 2020;147:619-632.
    PubMed     Abstract available


    June 2020
  22. WU D, Nie J, Hu W, Dai L, et al
    A phase II study of anlotinib in 45 patients with relapsed small cell lung cancer.
    Int J Cancer. 2020 Jun 18. doi: 10.1002/ijc.33161.
    PubMed     Abstract available


  23. URAKAWA H, Ando Y, Hase T, Kikumori T, et al
    Clinical value of serum bone resorption markers for predicting clinical outcomes after use of bone modifying agents in metastatic bone tumors: A prospective cohort study.
    Int J Cancer. 2020;146:3504-3515.
    PubMed     Abstract available


  24. DAGNINO S, Bodinier B, Grigoryan H, Rappaport SM, et al
    Agnostic Cys34-albumin adductomics and DNA methylation: Implication of N-acetylcysteine in lung carcinogenesis years before diagnosis.
    Int J Cancer. 2020;146:3294-3303.
    PubMed     Abstract available


  25. VELAZQUEZ-KRONEN R, Gilbert ES, Linet MS, Moysich KB, et al
    Lung cancer mortality associated with protracted low-dose occupational radiation exposures and smoking behaviors in U.S. radiologic technologists, 1983-2012.
    Int J Cancer. 2020 Jun 7. doi: 10.1002/ijc.33141.
    PubMed     Abstract available


  26. HOPKINS AM, Wagner J, Kichenadasse G, Modi N, et al
    Patient-reported outcomes as a prognostic marker of survival in patients with advanced non-small cell lung cancer treated with immunotherapy: PROs as a prognostic marker for immunotherapies.
    Int J Cancer. 2020 Jun 3. doi: 10.1002/ijc.33133.
    PubMed     Abstract available


  27. HOU HH, Pan HJ, Liao WY, Lee CH, et al
    Autophagy in fibroblasts induced by cigarette smoke extract promotes invasion in lung cancer cells.
    Int J Cancer. 2020 Jun 3. doi: 10.1002/ijc.33127.
    PubMed     Abstract available


    May 2020
  28. CAI H, Sobue T, Kitamura T, Ishihara J, et al
    Association between Meat and Saturated Fatty Acid Intake and Lung Cancer Risk: The Japan Public Health Center-based Prospective Study.
    Int J Cancer. 2020 May 22. doi: 10.1002/ijc.33112.
    PubMed     Abstract available


  29. TAKAMORI S, Takada K, Shimokawa M, Matsubara T, et al
    Predictive and prognostic impact of primary tumor-bearing lobe in non-small cell lung cancer patients treated with anti-PD-1 therapy.
    Int J Cancer. 2020 May 1. doi: 10.1002/ijc.33030.
    PubMed     Abstract available


  30. DONG S, Ruiz-Calderon B, Rathinam R, Eastlack S, et al
    Knockout model reveals the role of Nischarin in mammary gland development, breast tumorigenesis and response to metformin treatment.
    Int J Cancer. 2020;146:2576-2587.
    PubMed     Abstract available


  31. BERGQVIST M, Christensen HN, Wiklund F, Bergstrom S, et al
    Real world utilization of EGFR TKIs and prognostic factors for survival in NSCLC during 2010-2016 in Sweden: A nationwide observational study.
    Int J Cancer. 2020;146:2510-2517.
    PubMed     Abstract available


    March 2020
  32. FU F, Zhang Y, Gao Z, Zhao Y, et al
    Development and Validation of a Five-Gene Model to Predict Postoperative Brain Metastasis in Operable Lung Adenocarcinoma.
    Int J Cancer. 2020 Mar 17. doi: 10.1002/ijc.32981.
    PubMed     Abstract available


  33. KATO M, Onoyama I, Yoshida S, Cui L, et al
    Dual specificity phosphatase 6 plays a critical role in the maintenance of a cancer stem-like cell phenotype in human endometrial cancer.
    Int J Cancer. 2020 Mar 11. doi: 10.1002/ijc.32965.
    PubMed     Abstract available


  34. HELLMANN MD, Gettinger S, Chow LQM, Gordon M, et al
    Phase 1 Study of Epacadostat in Combination With Atezolizumab for Patients With Previously Treated Advanced Non-Small Cell Lung Cancer.
    Int J Cancer. 2020 Mar 6. doi: 10.1002/ijc.32951.
    PubMed     Abstract available


  35. QI L, Zhang Q, Miao Y, Kang W, et al
    Interleukin-33 activates and recruits natural killer cells to inhibit pulmonary metastatic cancer development.
    Int J Cancer. 2020;146:1421-1434.
    PubMed     Abstract available


    February 2020
  36. TANG D, Zhao YC, Liu H, Luo S, et al
    Potentially functional genetic variants in PLIN2, SULT2A1 and UGT1A9 genes of the Ketone pathway and survival of non-small cell lung cancer.
    Int J Cancer. 2020 Feb 18. doi: 10.1002/ijc.32932.
    PubMed     Abstract available


  37. BRASKY TM, Ray RM, Navarro SL, Schenk JM, et al
    Supplemental one-carbon metabolism related B vitamins and lung cancer risk in the Women's Health Initiative.
    Int J Cancer. 2020 Feb 6. doi: 10.1002/ijc.32913.
    PubMed     Abstract available


  38. FIDLER-BENAOUDIA MM, Torre LA, Bray F, Ferlay J, et al
    Lung cancer incidence in young women vs. young men: A systematic analysis in 40 countries.
    Int J Cancer. 2020 Feb 5. doi: 10.1002/ijc.32809.
    PubMed     Abstract available


    January 2020
  39. TRICKEY A, May MT, Gill MJ, Grabar S, et al
    Cause-specific mortality after diagnosis of cancer among HIV-positive patients: a collaborative analysis of cohort studies.
    Int J Cancer. 2020 Jan 31. doi: 10.1002/ijc.32895.
    PubMed     Abstract available


  40. HATA A, Nakajima T, Matsusaka K, Fukuyo M, et al
    A low DNA methylation epigenotype in lung squamous cell carcinoma and its association with idiopathic pulmonary fibrosis and poorer prognosis.
    Int J Cancer. 2020;146:388-399.
    PubMed     Abstract available


  41. LOPEZ-PLANA A, Fernandez-Nogueira P, Munoz-Guardiola P, Sole-Sanchez S, et al
    The novel pro-autophagy anticancer drug ABTL0812 potentiates chemotherapy in adenocarcinoma and squamous Non-Small Cell Lung Cancer.
    Int J Cancer. 2020 Jan 14. doi: 10.1002/ijc.32865.
    PubMed     Abstract available


  42. ZHANG L, Wang MJ, Wang W, Zhao JY, et al
    Identification of driver genes and somatic mutations in cell-free DNA of patients with pulmonary lymphangioleiomyomatosis.
    Int J Cancer. 2020;146:103-114.
    PubMed     Abstract available


    December 2019
  43. HSIEH YY, Fang WT, Lo YW, Chen YH, et al
    Comparing the Effectiveness of Different EGFR-TKIs in Patients with EGFR Mutant Non-Small-Cell Lung Cancer: A Retrospective Cohort Study in Taiwan.
    Int J Cancer. 2019 Dec 19. doi: 10.1002/ijc.32841.
    PubMed     Abstract available


  44. MOHRHERR J, Haber M, Breitenecker K, Aigner P, et al
    JAK-STAT inhibition impairs K-RAS-driven lung adenocarcinoma progression.
    Int J Cancer. 2019;145:3376-3388.
    PubMed     Abstract available


    November 2019
  45. BOECKX B, Bahadur Shahi R, Smeets D, De Brakeleer S, et al
    The genomic landscape of non-small cell lung carcinoma in never smokers.
    Int J Cancer. 2019 Nov 19. doi: 10.1002/ijc.32797.
    PubMed     Abstract available


  46. JIN R, Li J, Jin Z, Lu Y, et al
    Osimertinib confers potent binding affinity to EGFR kinase domain duplication.
    Int J Cancer. 2019;145:2884-2885.
    PubMed    


  47. WATZA D, Lusk CM, Dyson G, Purrington KS, et al
    COPD-dependent effects of genetic variation in key inflammation pathway genes on lung cancer risk.
    Int J Cancer. 2019 Nov 10. doi: 10.1002/ijc.32780.
    PubMed     Abstract available


  48. BOSSE Y, Li Z, Xia J, Manem V, et al
    Transcriptome-wide association study reveals candidate causal genes for lung cancer.
    Int J Cancer. 2019 Nov 6. doi: 10.1002/ijc.32771.
    PubMed     Abstract available


  49. DUAN W, Gao L, Kalvala A, Aguila B, et al
    Type of TP53 mutation influences oncogenic potential and spectrum of associated K-ras mutations in lung-specific transgenic mice.
    Int J Cancer. 2019;145:2418-2426.
    PubMed     Abstract available


    October 2019
  50. YANG S, Tang D, Zhao YC, Liu H, et al
    Novel genetic variants in KIF16B and NEDD4L in the endosome-related genes are associated with non-small cell lung cancer survival.
    Int J Cancer. 2019 Oct 16. doi: 10.1002/ijc.32739.
    PubMed     Abstract available


  51. QIAN J, Nie W, Lu J, Zhang L, et al
    Racial differences in characteristics and prognoses between Asian and white patients with non-small cell lung cancer receiving atezolizumab: an ancillary analysis of the POPLAR and OAK studies.
    Int J Cancer. 2019 Oct 3. doi: 10.1002/ijc.32717.
    PubMed     Abstract available


  52. STAPELFELD C, Dammann C, Maser E
    Sex-specificity in lung cancer risk.
    Int J Cancer. 2019 Oct 3. doi: 10.1002/ijc.32716.
    PubMed     Abstract available


  53. DAI J, Huang M, Amos CI, Hung RJ, et al
    Genome-wide association study of INDELs identified four novel susceptibility loci associated with lung cancer risk.
    Int J Cancer. 2019 Oct 2. doi: 10.1002/ijc.32698.
    PubMed     Abstract available


  54. KUANG M, Zheng D, Tao X, Peng Y, et al
    tRNA-based prognostic score in predicting survival outcomes of lung adenocarcinomas.
    Int J Cancer. 2019;145:1982-1990.
    PubMed     Abstract available


    September 2019
  55. WU DM, Deng SH, Zhou J, Han R, et al
    PLEK2 mediates metastasis and vascular invasion via the ubiquitin-dependent degradation of SHIP2 in non-small cell lung cancer.
    Int J Cancer. 2019 Sep 9. doi: 10.1002/ijc.32675.
    PubMed     Abstract available


  56. JIA Y, Li X, Jiang T, Zhao S, et al
    EGFR-targeted therapy alters the tumor microenvironment in EGFR-driven lung tumors: Implications for combination therapies.
    Int J Cancer. 2019;145:1432-1444.
    PubMed     Abstract available


  57. GRUNEWALD S, Politz O, Bender S, Heroult M, et al
    Rogaratinib: A potent and selective pan-FGFR inhibitor with broad antitumor activity in FGFR-overexpressing preclinical cancer models.
    Int J Cancer. 2019;145:1346-1357.
    PubMed     Abstract available


    August 2019
  58. KANG J, Chang Y, Ahn J, Oh S, et al
    Neutrophil-to-lymphocyte ratio and risk of lung cancer mortality in a low-risk population: A cohort study.
    Int J Cancer. 2019 Aug 27. doi: 10.1002/ijc.32640.
    PubMed     Abstract available


  59. NEMETH E, Krzystanek M, Reiniger L, Ribli D, et al
    The genomic imprint of cancer therapies helps timing the formation of metastases.
    Int J Cancer. 2019;145:694-704.
    PubMed     Abstract available


  60. VOLCKMAR AL, Leichsenring J, Kirchner M, Christopoulos P, et al
    Combined targeted DNA and RNA sequencing of advanced NSCLC in routine molecular diagnostics: Analysis of the first 3,000 Heidelberg cases.
    Int J Cancer. 2019;145:649-661.
    PubMed     Abstract available


    July 2019
  61. GURTNER K, Kryzmien Z, Koi L, Wang M, et al
    Radioresistance of KRAS/TP53-Mutated Lung Cancer can be overcome by Radiation Dose Escalation or EGFR Tyrosine Kinase Inhibition In Vivo.
    Int J Cancer. 2019 Jul 29. doi: 10.1002/ijc.32598.
    PubMed     Abstract available


  62. BAI L, Shin S, Burnett RT, Kwong JC, et al
    Exposure to ambient air pollution and the incidence of lung cancer and breast cancer in the Ontario Population Health and Environment Cohort (ONPHEC).
    Int J Cancer. 2019 Jul 15. doi: 10.1002/ijc.32575.
    PubMed     Abstract available


  63. KINOSHITA R, Sato H, Yamauchi A, Takahashi Y, et al
    Newly developed anti-S100A8/A9 monoclonal antibody efficiently prevents lung tropic cancer metastasis.
    Int J Cancer. 2019;145:569-575.
    PubMed     Abstract available


  64. HUANG JY, Larose TL, Luu HN, Wang R, et al
    Circulating markers of cellular immune activation in pre-diagnostic blood sample and lung cancer risk in the Lung Cancer Cohort Consortium (LC3).
    Int J Cancer. 2019 Jul 5. doi: 10.1002/ijc.32555.
    PubMed     Abstract available


  65. YI L, Fan J, Qian R, Luo P, et al
    Efficacy and safety of osimertinib in treating EGFR-mutated advanced NSCLC: A meta-analysis.
    Int J Cancer. 2019;145:284-294.
    PubMed     Abstract available


  66. BI L, Xie C, Yao M, Thae Hnit SS, et al
    The histone chaperone complex FACT promotes proliferative switch of G0 cancer cells.
    Int J Cancer. 2019;145:164-178.
    PubMed     Abstract available


    June 2019
  67. ZHANG L, Yang Y, Chai L, Bu H, et al
    FRK plays an oncogenic role in nonsmall cell lung cancer by enhancing the stemness phenotype via induction of metabolic reprogramming.
    Int J Cancer. 2019 Jun 28. doi: 10.1002/ijc.32530.
    PubMed     Abstract available


  68. KINOSHITA R, Sato H, Yamauchi A, Takahashi Y, et al
    exSSSRs (extracellular S100 soil sensor receptors)-Fc fusion proteins work as prominent decoys to S100A8/A9-induced lung tropic cancer metastasis.
    Int J Cancer. 2019;144:3138-3145.
    PubMed     Abstract available


  69. TAKASHIMA Y, Kikuchi E, Kikuchi J, Suzuki M, et al
    Bromodomain and Extraterminal Domain Inhibition Synergizes with WEE1-Inhibitor AZD1775 Effect by Impairing Non-Homologous End Joining and Enhancing DNA Damage in Non-Small Cell Lung Cancer.
    Int J Cancer. 2019 Jun 14. doi: 10.1002/ijc.32515.
    PubMed     Abstract available


  70. BECKER N, Motsch E, Trotter A, Heussel CP, et al
    Lung cancer mortality reduction by LDCT screening - results from the randomised German LUSI trial.
    Int J Cancer. 2019 Jun 4. doi: 10.1002/ijc.32486.
    PubMed     Abstract available


  71. LIU YN, Tsai MF, Wu SG, Chang TH, et al
    Acquired resistance to EGFR tyrosine kinase inhibitors is mediated by the reactivation of STC2/JUN/AXL signaling in lung cancer.
    Int J Cancer. 2019 Jun 4. doi: 10.1002/ijc.32487.
    PubMed     Abstract available


    May 2019
  72. GAO X, Wilsgaard T, Jansen EH, Xuan Y, et al
    Serum total thiol levels and the risk of lung, colorectal, breast and prostate cancer: A prospective case-cohort study.
    Int J Cancer. 2019 May 24. doi: 10.1002/ijc.32428.
    PubMed     Abstract available


  73. JIANG T, Chu Q, Wang H, Zhou F, et al
    EGFR-TKIs plus local therapy demonstrated survival benefit than EGFR-TKIs alone in EGFR-mutant NSCLC patients with oligometastatic or oligoprogressive liver metastases.
    Int J Cancer. 2019;144:2605-2612.
    PubMed     Abstract available


  74. ENDRIS V, Buchhalter I, Allgauer M, Rempel E, et al
    Measurement of tumor mutational burden (TMB) in routine molecular diagnostics: in silico and real-life analysis of three larger gene panels.
    Int J Cancer. 2019;144:2303-2312.
    PubMed     Abstract available


    April 2019
  75. QU J, Liu L, Xu Q, Ren J, et al
    CARD9 protects lung cancer development by suppressing the expansion of myeloid-derived suppressor cells and IDO production.
    Int J Cancer. 2019 Apr 22. doi: 10.1002/ijc.32355.
    PubMed     Abstract available


  76. D'ANDREA E, Choudhry NK, Raby B, Weinhouse GL, et al
    A bronchial-airway gene-expression classifier to improve the diagnosis of lung cancer: clinical outcomes and cost-effectiveness analysis.
    Int J Cancer. 2019 Apr 11. doi: 10.1002/ijc.32333.
    PubMed     Abstract available


  77. WANG S, Zhang J, He Z, Wu K, et al
    The predictive power of tumor mutational burden in lung cancer immunotherapy response is influenced by patients' sex.
    Int J Cancer. 2019 Apr 10. doi: 10.1002/ijc.32327.
    PubMed     Abstract available


  78. ZHANG B, Wu Q
    Erratum: The efficacy and safety of anti-PD-1/PD-L1 antibodies combined with chemotherapy or CTLA4 antibody as a first-line treatment for advanced lung cancer.
    Int J Cancer. 2019;144:E2.
    PubMed    


  79. WANG L, Zhao H, Xu Y, Li J, et al
    Systematic identification of lincRNA-based prognostic biomarkers by integrating lincRNA expression and copy number variation in lung adenocarcinoma.
    Int J Cancer. 2019;144:1723-1734.
    PubMed     Abstract available


    March 2019
  80. DIETZ S, Lifshitz A, Kazdal D, Harms A, et al
    Global DNA methylation reflects spatial heterogeneity and molecular evolution of lung adenocarcinomas.
    Int J Cancer. 2019;144:1061-1072.
    PubMed     Abstract available


    February 2019
  81. SHIN SH, Park HY, Im Y, Jung HA, et al
    Improved Treatment Outcome of Pembrolizumab in Patients with Non-small Cell Lung Cancer and Chronic Obstructive Pulmonary Disease.
    Int J Cancer. 2019 Feb 26. doi: 10.1002/ijc.32235.
    PubMed     Abstract available


  82. LEUNG EL, Luo LX, Li Y, Liu ZQ, et al
    Identification of a new inhibitor of KRAS-PDEdelta interaction targeting KRAS mutant non-small cell lung cancer.
    Int J Cancer. 2019 Feb 20. doi: 10.1002/ijc.32222.
    PubMed     Abstract available


  83. ZHANG C, Ding H, Huang H, Palashati H, et al
    TCR repertoire intratumor heterogeneity of CD4(+) and CD8(+) T cells in centers and margins of localized lung adenocarcinomas.
    Int J Cancer. 2019;144:818-827.
    PubMed     Abstract available


  84. SONG H, Sun B, Liao Y, Xu D, et al
    GPRC5A deficiency leads to dysregulated MDM2 via activated EGFR signaling for lung tumor development.
    Int J Cancer. 2019;144:777-787.
    PubMed     Abstract available


    January 2019
  85. YANG L, Dong Y, Li Y, Wang D, et al
    IL-10 derived from M2 macrophage promotes cancer stemness via JAK1/STAT1/NF-kappaB/Notch1 pathway in non-small cell lung cancer.
    Int J Cancer. 2019 Jan 22. doi: 10.1002/ijc.32151.
    PubMed     Abstract available


  86. LIU Y, Yang Q, Yang J, Cao R, et al
    Characteristics and prognostic significance of profiling the peripheral blood T-cell receptor repertoire in patients with advanced lung cancer.
    Int J Cancer. 2019 Jan 21. doi: 10.1002/ijc.32145.
    PubMed     Abstract available


  87. CHEN K, Liu H, Liu Z, Luo S, et al
    Genetic Variants in RUNX3, AMD1 and MSRA in the Methionine Metabolic Pathway and Survival in Non-small Cell Lung Cancer Patients.
    Int J Cancer. 2019 Jan 16. doi: 10.1002/ijc.32128.
    PubMed     Abstract available


  88. PAN Y, Yuan C, Cheng C, Zhang Y, et al
    Frequency and clinical significance of NF1 mutation in lung adenocarcinomas from East Asian patients.
    Int J Cancer. 2019;144:290-296.
    PubMed     Abstract available


  89. DU Y, Song W, Chen J, Chen H, et al
    The potassium channel KCa3.1 promotes cell proliferation by activating SKP2 and metastasis through the EMT pathway in hepatocellular carcinoma.
    Int J Cancer. 2019 Jan 10. doi: 10.1002/ijc.32121.
    PubMed     Abstract available


  90. DEVAUD C, Tilkin-Mariame AF, Vignolle-Vidoni A, Souleres P, et al
    FAK alternative splice mRNA variants expression pattern in colorectal cancer.
    Int J Cancer. 2019 Jan 10. doi: 10.1002/ijc.32120.
    PubMed     Abstract available


  91. WANG R, Peng S, Zhang X, Wu Z, et al
    Inhibition of NF-kappaB improves sensitivity to irradiation and EGFR-TKIs and decreases irradiation-induced lung toxicity.
    Int J Cancer. 2019;144:200-209.
    PubMed     Abstract available


  92. CHRISTOPOULOS P, Kirchner M, Bozorgmehr F, Endris V, et al
    Identification of a highly lethal V3(+) TP53(+) subset in ALK(+) lung adenocarcinoma.
    Int J Cancer. 2019;144:190-199.
    PubMed     Abstract available


    December 2018
  93. GAO X, Wilsgaard T, Jansen EH, Holleczek B, et al
    Pre-diagnostic derivatives of reactive oxygen metabolites and the occurrence of lung, colorectal, breast and prostate cancer: An individual participant data meta-analysis of two large population-based studies.
    Int J Cancer. 2018 Dec 18. doi: 10.1002/ijc.32073.
    PubMed     Abstract available


  94. LUO J, Chimge NO, Zhou B, Flodby P, et al
    CLDN18.1 attenuates malignancy and related signaling pathways of lung adenocarcinoma in vivo and in vitro.
    Int J Cancer. 2018;143:3169-3180.
    PubMed     Abstract available


  95. MARWITZ S, Heinbockel L, Scheufele S, Kugler C, et al
    Fountain of youth for squamous cell carcinomas? On the epigenetic age of non-small cell lung cancer and corresponding tumor-free lung tissues.
    Int J Cancer. 2018;143:3061-3070.
    PubMed     Abstract available


  96. LYU Z, Li N, Wang G, Feng X, et al
    Independent and joint associations of blood lipids and lipoproteins with lung cancer risk in Chinese males: A prospective cohort study.
    Int J Cancer. 2018 Dec 11. doi: 10.1002/ijc.32051.
    PubMed     Abstract available


  97. DE WIT S, Rossi E, Weber S, Tamminga M, et al
    Single tube liquid biopsy for advanced non-small cell lung cancer.
    Int J Cancer. 2018 Dec 11. doi: 10.1002/ijc.32056.
    PubMed    


  98. WONG JYY, Downward GS, Hu W, Portengen L, et al
    Lung Cancer Risk by Geologic Coal Deposits: A Case-Control Study of Female Never-smokers from Xuanwei and Fuyuan, China.
    Int J Cancer. 2018 Dec 3. doi: 10.1002/ijc.32034.
    PubMed     Abstract available


  99. GE Q, Lu M, Ju L, Qian K, et al
    miR-4324-RACGAP1-STAT3-ESR1 feedback loop inhibits proliferation and metastasis of bladder cancer.
    Int J Cancer. 2018 Dec 3. doi: 10.1002/ijc.32036.
    PubMed     Abstract available


  100. WU Y, Lin L, Shen Y, Wu H, et al
    Comparison between PD-1/PD-L1 inhibitors (nivolumab, pembrolizumab, and atezolizumab) in pretreated NSCLC patients: Evidence from a Bayesian network model.
    Int J Cancer. 2018;143:3038-3040.
    PubMed    


    November 2018
  101. FANIDI A, Carreras-Torres R, Larose TL, Yuan JM, et al
    Is high vitamin B12 status a cause of lung cancer?
    Int J Cancer. 2018 Nov 29. doi: 10.1002/ijc.32033.
    PubMed     Abstract available


  102. LIN YT, Chen JS, Liao WY, Ho CC, et al
    Clinical Outcomes and Secondary Epidermal Growth Factor Receptor (EGFR) T790M Mutation among First-line Gefitinib, Erlotinib and Afatinib-treated Non-small Cell Lung Cancer Patients with Activating EGFR Mutations.
    Int J Cancer. 2018 Nov 28. doi: 10.1002/ijc.32025.
    PubMed     Abstract available


  103. WANG S, Yan B, Zhang Y, Xu J, et al
    Different characteristics and survival in non-small cell lung cancer patients with primary and acquired EGFR T790M mutation.
    Int J Cancer. 2018 Nov 25. doi: 10.1002/ijc.32015.
    PubMed     Abstract available


  104. ZHENG S, Luo X, Dong C, Zheng D, et al
    A B7-CD28 family based signature demonstrates significantly different prognoses and tumor immune landscapes in lung adenocarcinoma.
    Int J Cancer. 2018;143:2592-2601.
    PubMed     Abstract available


  105. NARDI I, Reno T, Yun X, Sztain T, et al
    Triptolide inhibits Wnt signaling in NSCLC through upregulation of multiple Wnt inhibitory factors via epigenetic modifications to Histone H3.
    Int J Cancer. 2018;143:2470-2478.
    PubMed     Abstract available


  106. ZHAO S, Zhang Z, Zhang Y, Hong S, et al
    Progression-free survival and one-year milestone survival as surrogates for overall survival in previously treated advanced non-small cell lung cancer.
    Int J Cancer. 2018 Nov 14. doi: 10.1002/ijc.31995.
    PubMed     Abstract available


  107. FORTUNATO O, Borzi C, Milione M, Centonze G, et al
    Circulating mir-320a promotes immunosuppressive macrophages M2 phenotype associated with lung cancer risk.
    Int J Cancer. 2018 Nov 13. doi: 10.1002/ijc.31988.
    PubMed     Abstract available


  108. POTJER TP, Bollen S, Grimbergen AJEM, van Doorn R, et al
    Multi-gene panel sequencing of established and candidate melanoma susceptibility genes in a large cohort of Dutch non-CDKN2A/CDK4 melanoma families.
    Int J Cancer. 2018 Nov 10. doi: 10.1002/ijc.31984.
    PubMed     Abstract available


  109. CAI MC, Chen M, Ma P, Wu J, et al
    Clinicopathological, microenvironmental and genetic determinants of molecular subtypes in KEAP1/NRF2-mutant lung cancer.
    Int J Cancer. 2018 Nov 8. doi: 10.1002/ijc.31975.
    PubMed     Abstract available


    October 2018
  110. XIA Y, Cai XY, Fan JQ, Zhang LL, et al
    The role of sema4D in vasculogenic mimicry formation in non-small cell lung cancer and the underlying mechanisms.
    Int J Cancer. 2018 Oct 29. doi: 10.1002/ijc.31958.
    PubMed     Abstract available


  111. LI W, Sparidans RW, Wang Y, Lebre MC, et al
    P-glycoprotein (MDR1/ABCB1) restricts brain accumulation and cytochrome P450-3A (CYP3A) limits oral availability of the novel ALK/ROS1 inhibitor lorlatinib.
    Int J Cancer. 2018;143:2029-2038.
    PubMed     Abstract available


  112. YANG YG, Koh YW, Sari IN, Jun N, et al
    Interferon-induced transmembrane protein 1-mediated EGFR/SOX2 signaling axis is essential for progression of non-small cell lung cancer.
    Int J Cancer. 2018 Oct 14. doi: 10.1002/ijc.31926.
    PubMed     Abstract available


  113. MATSUO N, Azuma K, Hattori S, Ohtake J, et al
    Association between soluble immune mediators and tumor responses in patients with non-small cell lung cancer treated with anti-PD-1 inhibitor.
    Int J Cancer. 2018 Oct 11. doi: 10.1002/ijc.31923.
    PubMed     Abstract available


    September 2018
  114. QIAN D, Liu H, Wang X, Ge J, et al
    Potentially functional genetic variants in the complement-related immunity gene-set are associated with non-small cell lung cancer survival.
    Int J Cancer. 2018 Sep 27. doi: 10.1002/ijc.31896.
    PubMed     Abstract available


  115. TREUE D, Bockmayr M, Stenzinger A, Heim D, et al
    Proteogenomic systems analysis identifies targeted therapy resistance mechanisms in EGFR-mutated lung cancer.
    Int J Cancer. 2018 Sep 5. doi: 10.1002/ijc.31845.
    PubMed     Abstract available


  116. MAEDA T, Hayashi T, Furukawa H, Iwasaki D, et al
    Immune-mediated antitumor effect of a transplanted lymph node.
    Int J Cancer. 2018;143:1224-1235.
    PubMed     Abstract available


  117. GARCIA-MONCLUS S, Lopez-Alemany R, Almacellas-Rabaiget O, Herrero-Martin D, et al
    EphA2 receptor is a key player in the metastatic onset of Ewing sarcoma.
    Int J Cancer. 2018;143:1188-1201.
    PubMed     Abstract available


  118. XU H, Zhu X, Bao H, Wh Shek T, et al
    Genetic and clonal dissection of osteosarcoma progression and lung metastasis.
    Int J Cancer. 2018;143:1134-1142.
    PubMed     Abstract available


    August 2018
  119. LEHMAN JM, Hoeksema MD, Staub J, Qian J, et al
    Somatostatin Receptor 2 signaling promotes growth and tumor survival in Small Cell Lung Cancer.
    Int J Cancer. 2018 Aug 28. doi: 10.1002/ijc.31771.
    PubMed     Abstract available


  120. JIANG Y, Dai H, Li Y, Yin J, et al
    PARP Inhibitors Synergize with Gemcitabine by Potentiating DNA Damage in Non-Small Cell Lung Cancer.
    Int J Cancer. 2018 Aug 28. doi: 10.1002/ijc.31770.
    PubMed     Abstract available


    July 2018
  121. YUAN Q, Chen X, Han Y, Lei T, et al
    Modification of alpha2,6-sialylation mediates the invasiveness and tumorigenicity of non-small cell lung cancer cells in vitro and in vivo via Notch1/Hes1/MMPs pathway.
    Int J Cancer. 2018 Jul 7. doi: 10.1002/ijc.31737.
    PubMed     Abstract available


  122. XU Y, Liu H, Liu S, Wang Y, et al
    Genetic variant of IRAK2 in the toll-like receptor signaling pathway and survival of non-small cell lung cancer.
    Int J Cancer. 2018 Jul 6. doi: 10.1002/ijc.31660.
    PubMed     Abstract available


  123. YANG CC, Chang CK, Chang MT, Shyur LF, et al
    Plant galactolipid dLGG suppresses lung metastasis of melanoma through deregulating TNF-alpha-mediated pulmonary vascular permeability and circulating oxylipin dynamics in mice.
    Int J Cancer. 2018 Jul 6. doi: 10.1002/ijc.31663.
    PubMed     Abstract available


  124. WU Y, Ju Q, Jia K, Yu J, et al
    Correlation between sex and efficacy of immune checkpoint inhibitors (PD-1 and CTLA-4 inhibitors).
    Int J Cancer. 2018;143:45-51.
    PubMed     Abstract available


  125. TAN J, Fu L, Chen H, Guan J, et al
    Association study of genetic variation in the autophagy lysosome pathway genes and risk of eight kinds of cancers.
    Int J Cancer. 2018;143:80-87.
    PubMed     Abstract available


    June 2018
  126. LEE YM, Kim SJ, Lee JH, Ha E, et al
    Inhaled corticosteroids in COPD and the risk of lung cancer.
    Int J Cancer. 2018 Jun 26. doi: 10.1002/ijc.31632.
    PubMed     Abstract available


  127. BOYSEN AK, Spindler KL, Hoyer M, Mortensen FV, et al
    Metastasis directed therapy for liver and lung metastases from colorectal cancer - a population based study.
    Int J Cancer. 2018 Jun 19. doi: 10.1002/ijc.31626.
    PubMed     Abstract available


  128. LUU HN, Cai H, Murff HJ, Xiang YB, et al
    A Prospective Study of Dietary Polyunsaturated Fatty Acids Intake and Lung Cancer Risk.
    Int J Cancer. 2018 Jun 15. doi: 10.1002/ijc.31608.
    PubMed     Abstract available


  129. LINDNER LH, Litiere S, Sleijfer S, Benson C, et al
    Prognostic factors for soft tissue sarcoma patients with lung metastases only who are receiving first-line chemotherapy: An exploratory, retrospective analysis of the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarc
    Int J Cancer. 2018;142:2610-2620.
    PubMed     Abstract available


  130. CHRISTOPOULOS P, Endris V, Bozorgmehr F, Elsayed M, et al
    EML4-ALK fusion variant V3 is a high-risk feature conferring accelerated metastatic spread, early treatment failure and worse overall survival in ALK(+) non-small cell lung cancer.
    Int J Cancer. 2018;142:2589-2598.
    PubMed     Abstract available


  131. WANG H, Zhang X, Vidaurre I, Cai R, et al
    Inhibition of experimental small-cell and non-small-cell lung cancers by novel antagonists of growth hormone-releasing hormone.
    Int J Cancer. 2018;142:2394-2404.
    PubMed     Abstract available


  132. YUAN JM, Beckman KB, Wang R, Bull C, et al
    Leukocyte telomere length in relation to risk of lung adenocarcinoma incidence: Findings from the Singapore Chinese Health Study.
    Int J Cancer. 2018;142:2234-2243.
    PubMed     Abstract available


    May 2018
  133. VON NEUBECK B, Gondi G, Riganti C, Pan C, et al
    An inhibitory antibody targeting Carbonic Anhydrase XII abrogates chemoresistance and significantly reduces lung metastases in an orthotopic breast cancer model in vivo.
    Int J Cancer. 2018 May 22. doi: 10.1002/ijc.31607.
    PubMed     Abstract available


  134. LA MANNA S, Lee E, Ouzounova M, Di Natale C, et al
    Mimetics of Suppressor of cytokine signalling 3: novel potential therapeutics in triple breast cancer.
    Int J Cancer. 2018 May 11. doi: 10.1002/ijc.31594.
    PubMed     Abstract available


  135. OH E, Kim YJ, An H, Sung D, et al
    Flubendazole elicits anti-metastatic effects in triple-negative breast cancer via STAT3 inhibition.
    Int J Cancer. 2018 May 9. doi: 10.1002/ijc.31585.
    PubMed     Abstract available


  136. TZENG HT, Su CC, Chang CP, Lai WW, et al
    Rab37 in lung cancer mediates exocytosis of soluble ST2 and thus skews macrophages towards tumor-suppressing phenotype.
    Int J Cancer. 2018 May 1. doi: 10.1002/ijc.31569.
    PubMed     Abstract available


  137. XIE J, Shen K, Lenchine RV, Gethings LA, et al
    Eukaryotic elongation factor 2 kinase upregulates the expression of proteins implicated in cell migration and cancer cell metastasis.
    Int J Cancer. 2018;142:1865-1877.
    PubMed     Abstract available


    April 2018
  138. LA FLEUR L, Boura VF, Alexeyenko A, Berglund A, et al
    Expression of scavenger receptor MARCO defines a targetable tumor-associated macrophage subset in non-small cell lung cancer.
    Int J Cancer. 2018 Apr 18. doi: 10.1002/ijc.31545.
    PubMed     Abstract available


    March 2018
  139. HYNDS RE, Ben Aissa A, Gowers KHC, Watkins TBK, et al
    Expansion of airway basal epithelial cells from primary human non-small cell lung cancer tumors.
    Int J Cancer. 2018 Mar 22. doi: 10.1002/ijc.31383.
    PubMed     Abstract available


  140. BOYAR CETINKAYA R, Aagnes B, Myklebust TA, Thiis-Evensen E, et al
    Survival in neuroendocrine neoplasms; A report from a large Norwegian population-based study.
    Int J Cancer. 2018;142:1139-1147.
    PubMed     Abstract available


  141. PASSIGLIA F, Galvano A, Rizzo S, Incorvaia L, et al
    Looking for the best immune-checkpoint inhibitor in pre-treated NSCLC patients: An indirect comparison between nivolumab, pembrolizumab and atezolizumab.
    Int J Cancer. 2018;142:1277-1284.
    PubMed     Abstract available


  142. GAO Y, Yang J, Cai Y, Fu S, et al
    IFN-gamma-mediated inhibition of lung cancer correlates with PD-L1 expression and is regulated by PI3K-AKT signaling.
    Int J Cancer. 2018 Mar 8. doi: 10.1002/ijc.31357.
    PubMed     Abstract available


  143. WANG Y, Wang C, Zhang J, Zhu M, et al
    Interaction analysis between germline susceptibility loci and somatic alterations in lung cancer.
    Int J Cancer. 2018 Mar 1. doi: 10.1002/ijc.31351.
    PubMed     Abstract available


    February 2018
  144. WEI Y, Zhou F, Zhou H, Huang J, et al
    Endothelial progenitor cells contribute to neovascularization of non-small cell lung cancer via HDAC7 mediated cytoskeleton regulation and angiogenic genes transcription.
    Int J Cancer. 2018 Feb 28. doi: 10.1002/ijc.31349.
    PubMed     Abstract available


  145. CHO J, Kim S, Du J, Meyerson M, et al
    Autophosphorylation of the C-terminal domain is not required for oncogenic transformation by lung-cancer derived EGFR mutants.
    Int J Cancer. 2018 Feb 21. doi: 10.1002/ijc.31332.
    PubMed     Abstract available


  146. LI X, Wang Y, Wang J, Zhang T, et al
    Enhanced efficacy of AZD3759 and radiation on brain metastasis from EGFR mutant non-small cell lung cancer.
    Int J Cancer. 2018 Feb 12. doi: 10.1002/ijc.31303.
    PubMed     Abstract available


  147. JIANG Z, Chen T, Chen J, Ying S, et al
    Hand-spinning chrysotile exposure and risk of malignant mesothelioma: A case-control study in Southeastern China.
    Int J Cancer. 2018;142:514-523.
    PubMed     Abstract available


    January 2018
  148. NARITA S, Saito E, Sawada N, Shimazu T, et al
    Dietary Consumption of Antioxidant Vitamins and Subsequent Lung Cancer Risk: The Japan Public Health Center-based Prospective Study.
    Int J Cancer. 2018 Jan 22. doi: 10.1002/ijc.31268.
    PubMed     Abstract available


  149. SETTE G, Salvati V, Giordani I, Pillozzi E, et al
    Conditionally reprogrammed cells (CRC) methodology does not allow the in vitro expansion of patient-derived primary and metastatic lung cancer cells.
    Int J Cancer. 2018 Jan 17. doi: 10.1002/ijc.31260.
    PubMed     Abstract available


  150. INOUE-CHOI M, Hartge P, Liao LM, Caporaso N, et al
    Association between long-term low-intensity cigarette smoking and incidence of smoking-related cancer in the national institutes of health-AARP cohort.
    Int J Cancer. 2018;142:271-280.
    PubMed     Abstract available


  151. XU X, Huang Z, Zheng L, Fan Y, et al
    The efficacy and safety of anti-PD-1/PD-L1 antibodies combined with chemotherapy or CTLA4 antibody as a first-line treatment for advanced lung cancer.
    Int J Cancer. 2018 Jan 10. doi: 10.1002/ijc.31252.
    PubMed     Abstract available


  152. MORRIS S, Vachani A, Pass HI, Rom WN, et al
    Whole Blood FPR1 mRNA Expression Predicts Both Non-Small Cell and Small Cell Lung Cancer.
    Int J Cancer. 2018 Jan 5. doi: 10.1002/ijc.31245.
    PubMed     Abstract available


  153. YANG TY, Teng CJ, Lin TC, Chen KC, et al
    Transcriptional repression of Aurora-A gene by wild-type p53 through directly binding to its promoter with histone deacetylase 1 and mSin3a.
    Int J Cancer. 2018;142:92-108.
    PubMed     Abstract available


    December 2017
  154. DAI L, Smith CD, Foroozesh M, Miele L, et al
    The sphingosine kinase 2 inhibitor ABC294640 displays anti-non-small cell lung cancer activities in vitro and in vivo.
    Int J Cancer. 2017 Dec 26. doi: 10.1002/ijc.31234.
    PubMed     Abstract available


  155. YU Y, Jin H, Xu J, Gu J, et al
    XIAP overexpression promotes bladder cancer invasion in vitro and lung metastasis in vivo via enhancing nucleolin-mediated Rho-GDIbeta mRNA stability.
    Int J Cancer. 2017 Dec 18. doi: 10.1002/ijc.31223.
    PubMed     Abstract available


  156. WU Y, Shi H, Jiang M, Qiu M, et al
    The clinical value of combination of immune checkpoint inhibitors in cancer patients: A meta-analysis of efficacy and safety.
    Int J Cancer. 2017;141:2562-2570.
    PubMed     Abstract available


  157. THEOFYLAKTOPOULOU D, Midttun O, Ueland PM, Meyer K, et al
    Impaired functional vitamin B6 status is associated with increased risk of lung cancer.
    Int J Cancer. 2017 Dec 14. doi: 10.1002/ijc.31215.
    PubMed     Abstract available


  158. ZHENG Y, Deng Z, Yin J, Wang S, et al
    The association of genetic variations in DNA repair pathways with severe toxicities in NSCLC patients undergoing platinum-based chemotherapy.
    Int J Cancer. 2017;141:2336-2347.
    PubMed     Abstract available


  159. DETTERBECK FC
    Letter to the Editor: Re: The Impact of Overdiagnosis on the Selection of Efficient Lung Cancer Screening Strategies.
    Int J Cancer. 2017 Dec 1. doi: 10.1002/ijc.31185.
    PubMed    


    November 2017
  160. WANG Y, Wu W, Zhu M, Wang C, et al
    Integrating expression related SNPs into genome-wide gene-pathway-based analysis identified novel lung cancer susceptibility genes.
    Int J Cancer. 2017 Nov 30. doi: 10.1002/ijc.31182.
    PubMed     Abstract available


  161. ZHAO S, Gao F, Zhang Y, Zhang Z, et al
    Bevacizumab in Combination with Different Platinum-based Doublets in the First-line Treatment for Advanced Nonsquamous Non-small-cell Lung Cancer: A Network Meta-Analysis.
    Int J Cancer. 2017 Nov 24. doi: 10.1002/ijc.31175.
    PubMed     Abstract available


  162. LI Y, Ye Z, Chen S, Pan Z, et al
    ARHGEF19 interacts with BRAF to activate MAPK signaling during the tumorigenesis of non-small cell lung cancer.
    Int J Cancer. 2017 Nov 22. doi: 10.1002/ijc.31169.
    PubMed     Abstract available


  163. SATTERFIELD L, Shuck R, Kurenbekova L, Allen-Rhoades W, et al
    miR-130b directly targets ARHGAP1 to drive activation of a metastatic CDC42-PAK1-AP1 positive feedback loop in Ewing sarcoma.
    Int J Cancer. 2017;141:2062-2075.
    PubMed     Abstract available


  164. KIM J, Field A, Schultz KAP, Hill DA, et al
    The prevalence of DICER1 pathogenic variation in population databases.
    Int J Cancer. 2017;141:2030-2036.
    PubMed     Abstract available


  165. UNVER N, Delgado O, Zeleke K, Cumpian A, et al
    Reduced IL-6 levels and tumor-associated phospho-STAT3 are associated with reduced tumor development in a mouse model of lung cancer chemoprevention with myo-inositol.
    Int J Cancer. 2017 Nov 14. doi: 10.1002/ijc.31152.
    PubMed     Abstract available


  166. ZHANG R, Jia M, Xu Y, Qian D, et al
    ERCC4 regulatory variant predict Grade-3 or -4 toxicities in patients with advanced non-small cell lung cancer treated by platinum-based therapy.
    Int J Cancer. 2017 Nov 14. doi: 10.1002/ijc.31153.
    PubMed     Abstract available


  167. DIETZ S, Harms A, Endris V, Eichhorn F, et al
    Spatial distribution of EGFR and KRAS mutation frequencies correlates with histological growth patterns of lung adenocarcinomas.
    Int J Cancer. 2017;141:1841-1848.
    PubMed     Abstract available


    October 2017
  168. FUJIMOTO J, Nunomura-Nakamura S, Liu Y, Lang W, et al
    Development of Kras mutant lung adenocarcinoma in mice with knockout of the airway lineage-specific gene Gprc5a.
    Int J Cancer. 2017;141:1589-1599.
    PubMed     Abstract available


  169. LIU HX, Tao LL, Zhang J, Zhu YG, et al
    Difference of lower airway microbiome in bilateral protected specimen brush between lung cancer patients with unilateral lobar masses and control subjects.
    Int J Cancer. 2017 Oct 11. doi: 10.1002/ijc.31098.
    PubMed     Abstract available


    September 2017
  170. BRYANT JL, Gieling RG, Meredith SL, Allen TJ, et al
    Novel carbonic anhydrase IX-targeted therapy enhances the anti-tumour effects of cisplatin in small cell lung cancer.
    Int J Cancer. 2017 Sep 14. doi: 10.1002/ijc.31042.
    PubMed     Abstract available


    August 2017
  171. ZHANG K, Wang J, Tong TR, Wu X, et al
    Loss of H2B monoubiquitination is associated with poor-differentiation and enhanced malignancy of lung adenocarcinoma.
    Int J Cancer. 2017;141:766-777.
    PubMed     Abstract available


  172. GUPTA SK, Guzman EAT, Meenach SA
    Co-administration of a tumor-penetrating peptide improves the therapeutic efficacy of paclitaxel in a novel air-grown lung cancer 3D spheroid model.
    Int J Cancer. 2017 Aug 2. doi: 10.1002/ijc.30913.
    PubMed     Abstract available


    July 2017
  173. LI W, Xie SH, Tse LA, Lagergren J, et al
    Digitalis Use and Lung Cancer Risk by Histological Type in Men.
    Int J Cancer. 2017 Jul 27. doi: 10.1002/ijc.30908.
    PubMed     Abstract available


  174. MORAVCIKOVA E, Krepela E, Donnenberg VS, Donnenberg AD, et al
    BOK displays cell death-independent tumor suppressor activity in non-small cell lung carcinoma.
    Int J Cancer. 2017 Jul 26. doi: 10.1002/ijc.30906.
    PubMed     Abstract available


  175. KETTUNEN E, Hernandez-Vargas H, Cros MP, Durand G, et al
    Asbestos-associated genome-wide DNA methylation changes in lung cancer.
    Int J Cancer. 2017 Jul 19. doi: 10.1002/ijc.30897.
    PubMed     Abstract available


  176. LEE WY, Chen PC, Wu WS, Wu HC, et al
    Panobinostat Sensitizes KRAS-Mutant Non-Small Cell Lung Cancer to Gefitinib by Targeting TAZ.
    Int J Cancer. 2017 Jul 14. doi: 10.1002/ijc.30888.
    PubMed     Abstract available


  177. GU F, Zhang H, Hyland PL, Berndt S, et al
    Inherited variation in circadian rhythm genes and risks of prostate cancer and three other cancer sites in combined cancer consortia.
    Int J Cancer. 2017 Jul 12. doi: 10.1002/ijc.30883.
    PubMed     Abstract available


  178. KNIPS J, Czech-Sioli M, Spohn M, Heiland M, et al
    Spontaneous lung metastasis formation of human Merkel cell carcinoma cell lines transplanted into scid mice.
    Int J Cancer. 2017;141:160-171.
    PubMed     Abstract available


    May 2017
  179. XIE K, Chen M, Zhu M, Wang C, et al
    A polymorphism in miR-1262 regulatory region confers the risk of lung cancer in Chinese population.
    Int J Cancer. 2017 May 16. doi: 10.1002/ijc.30788.
    PubMed     Abstract available


  180. NAJMEH S, Cools-Lartigue J, Rayes RF, Gowing S, et al
    Neutrophil extracellular traps sequester circulating tumor cells via beta1-integrin mediated interactions.
    Int J Cancer. 2017;140:2321-2330.
    PubMed     Abstract available


  181. MEYERS TJ, Chang SC, Chang PY, Morgenstern H, et al
    Case-control study of cumulative cigarette tar exposure and lung and upper aerodigestive tract cancers.
    Int J Cancer. 2017;140:2040-2050.
    PubMed     Abstract available


    April 2017
  182. LOBB RJ, van Amerongen R, Wiegmans A, Ham S, et al
    Exosomes derived from mesenchymal non-small cell lung cancer cells promote chemoresistance.
    Int J Cancer. 2017 Apr 26. doi: 10.1002/ijc.30752.
    PubMed     Abstract available


  183. BEN KHEDHER S, Neri M, Papadopoulos A, Christiani DC, et al
    Menstrual and reproductive factors and lung cancer risk: A pooled analysis from the International Lung Cancer consortium (ILCCO).
    Int J Cancer. 2017 Apr 25. doi: 10.1002/ijc.30750.
    PubMed     Abstract available


  184. WANG SS, Zimmermann M, Zhang H, Lin TY, et al
    A Diagnostic Microdosing Approach to Investigate Platinum Sensitivity in Non-Small Cell Lung Cancer.
    Int J Cancer. 2017 Apr 24. doi: 10.1002/ijc.30747.
    PubMed     Abstract available


  185. GROMOWSKI T, Gapska P, Scott RJ, Kaklewski K, et al
    Serum 25(OH)D concentration, common variants of the VDR gene and lung cancer occurrence.
    Int J Cancer. 2017 Apr 15. doi: 10.1002/ijc.30740.
    PubMed     Abstract available


  186. GOWING SD, Chow SC, Cools-Lartigue JJ, Chen CB, et al
    Gram-Positive Pneumonia Augments Non-Small Cell Lung Cancer Metastasis Via Host Toll-like Receptor 2 Activation.
    Int J Cancer. 2017 Apr 12. doi: 10.1002/ijc.30734.
    PubMed     Abstract available


  187. CAROZZI FM, Bisanzi S, Carrozzi L, Falaschi F, et al
    Multimodal lung cancer screening using the ITALUNG Biomarker Panel and Low Dose Computed Tomography. Results of the ITALUNG biomarker study.
    Int J Cancer. 2017 Apr 7. doi: 10.1002/ijc.30727.
    PubMed     Abstract available


  188. HELLAND A, Brustugun OT, Nakken S, Halvorsen AR, et al
    High number of kinome-mutations in non-small cell lung cancer is associated with reduced immune response and poor relapse-free survival.
    Int J Cancer. 2017 Apr 7. doi: 10.1002/ijc.30726.
    PubMed     Abstract available


  189. LIN J, Gill A, Zahm SH, Carter CA, et al
    Metformin Use and Survival after Non-Small Cell Lung Cancer: A Cohort Study in the U.S. Military Health System.
    Int J Cancer. 2017 Apr 5. doi: 10.1002/ijc.30724.
    PubMed     Abstract available


  190. FRANK C, Sundquist J, Yu H, Hemminki A, et al
    Concordant and discordant familial cancer: Familial risks, proportions and population impact.
    Int J Cancer. 2017;140:1510-1516.
    PubMed     Abstract available


  191. RAASCHOU-NIELSEN O, Pedersen M, Stafoggia M, Weinmayr G, et al
    Outdoor air pollution and risk for kidney parenchyma cancer in 14 European cohorts.
    Int J Cancer. 2017;140:1528-1537.
    PubMed     Abstract available


  192. TANG Z, Li J, Shen Q, Feng J, et al
    Contribution of upregulated dipeptidyl peptidase 9 (DPP9) in promoting tumoregenicity, metastasis and the prediction of poor prognosis in non-small cell lung cancer (NSCLC).
    Int J Cancer. 2017;140:1620-1632.
    PubMed     Abstract available


    March 2017
  193. DONG J, Cheng Y, Zhu M, Wen Y, et al
    Fine Mapping of Chromosome 5p15.33 Identifies Novel Lung Cancer Susceptibility Loci in Han Chinese.
    Int J Cancer. 2017 Mar 23. doi: 10.1002/ijc.30702.
    PubMed     Abstract available


  194. GOLDWASSER DL
    Estimation of the tumor size at cure threshold among aggressive non-small cell lung cancers (NSCLCs): evidence from the surveillance, epidemiology, and end results (SEER) program and the national lung screening trial (NLST).
    Int J Cancer. 2017;140:1280-1292.
    PubMed     Abstract available


  195. SHI H, Zhang J, Han X, Li H, et al
    Recruited monocytic myeloid-derived suppressor cells promote the arrest of tumor cells in the premetastatic niche through an IL-1beta-mediated increase in E-selectin expression.
    Int J Cancer. 2017;140:1370-1383.
    PubMed     Abstract available


    January 2017
  196. ZHANG LL, Kan M, Zhang MM, Yu SS, et al
    Multiregion sequencing reveals the intratumor heterogeneity of driver mutations in TP53-driven non-small cell lung cancer.
    Int J Cancer. 2017;140:103-108.
    PubMed     Abstract available


  197. KAMMERER-JACQUET SF, Crouzet L, Brunot A, Dagher J, et al
    Independent association of PD-L1 expression with noninactivated VHL clear cell renal cell carcinoma-A finding with therapeutic potential.
    Int J Cancer. 2017;140:142-148.
    PubMed     Abstract available


  198. VAZQUEZ R, Licandro SA, Astorgues-Xerri L, Lettera E, et al
    Promising in vivo efficacy of the BET bromodomain inhibitor OTX015/MK-8628 in malignant pleural mesothelioma xenografts.
    Int J Cancer. 2017;140:197-207.
    PubMed     Abstract available


    December 2016
  199. MANDRIOTA SJ, Tenan M, Ferrari P, Sappino AP, et al
    Aluminium chloride promotes tumorigenesis and metastasis in normal murine mammary gland epithelial cells.
    Int J Cancer. 2016;139:2781-2790.
    PubMed     Abstract available


    November 2016
  200. LI L, Yang L, Wang L, Wang F, et al
    Impaired T cell function in malignant pleural effusion is caused by TGF-beta derived predominantly from macrophages.
    Int J Cancer. 2016;139:2261-9.
    PubMed     Abstract available


    October 2016
  201. TRABERT B, Eldridge RC, Pfeiffer RM, Shiels MS, et al
    Pre-diagnostic circulating inflammation markers and endometrial cancer risk in the Prostate, Lung, Colorectal and Ovarian Cancer (PLCO) Screening Trial.
    Int J Cancer. 2016 Oct 22. doi: 10.1002/ijc.30478.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Lung Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: